| Autor: |
Rahmawati, Septyana Eka, Nugraha, Jusak, Indah Budhy, S. Theresia |
| Předmět: |
|
| Zdroj: |
AIP Conference Proceedings; 2023, Vol. 2739 Issue 1, p1-10, 10p |
| Abstrakt: |
The presence of a cytokine storm in COVID-19 patients increases the severity of the disease and increases mortality. The administration of convalescent plasma therapy in COVID-19 patients is still the treatment of choice until now. The principle of convalescent plasma therapy is the transfer of passive antibodies so that they function as neutralizing antibodies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Convalescent plasma therapy has shown to reduce clinical symptoms to the recovery stage in COVID-19 patients. One of the targets of this therapy is to reduce the cytokine storm. The roles of IL-21 and IL-27 in COVID-19 patients receiving convalescent plasma therapy have not been studied in detail. Therefore, we will review the role of IL-21 and IL-27 in COVID-19 patients given convalescent plasma. The method used in collecting articles for the publication year 2020-2021 uses the keywords "SARS-COV-2", "Tfh cell", "Interleukin-21", "Interleukin-27", "COVID-19" and "Convalescent plasma " The results of the review described an increase in IL-21 associated with antibody production. The levels of IL-21 and Il-27 in convalescent plasma donors still form antibodies in their plasma cells. The higher the level of IL-27, the higher the level of IL-21 so that more antibodies are formed. The amount of antibodies formed will be useful for recipients who are in need for recovery from Sars-Cov-2. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
